Mercaptamine bitartrate controlled-release

Drug Profile

Mercaptamine bitartrate controlled-release

Alternative Names: Cysteamine bitartrate delayed-release; Delayed-release cysteamine; DR cysteamine; DR mercaptamine bitartrate; EC cysteamine; EC cysteamine bitartrate; EC mercaptamine bitartrate; Gastro-resistant cysteamine; Mercaptamine bitartrate delayed-release; PROCYSBI; RP-103; RP-104

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Horizon Pharma; National Institute of Diabetes and Digestive and Kidney Diseases; Raptor Pharmaceutical Corp
  • Class Mercaptoethylamines; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antimetabolites; Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis; Huntington's disease; Cystinosis
  • New Molecular Entity No
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Marketed Nephropathic cystinosis
  • Phase II/III Huntington's disease; Leigh disease; Mitochondrial disorders
  • Phase II Non-alcoholic steatohepatitis
  • Preclinical Malaria
  • Discontinued Neuronal ceroid lipofuscinosis

Most Recent Events

  • 06 Mar 2017 Raptor Pharmaceuticals completes a phase II extension trial for Mitochondrial disorders (In children, In adolescents) in USA (NCT02473445)
  • 13 Dec 2016 Raptor completes a phase III trial for Nephropathic cystinosis in USA (NCT01744782)
  • 01 Oct 2016 Raptor Pharmaceuticals completes a phase-II/III trial in Leigh disease and mitochondrial disorders (in children and adolescents) in USA (PO) (NCT02023866)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top